 lymphokine-activ killer cell children advanc metastat neuroblastoma phase II trial lymphokine-activ killer lak cell attempt children end-stag neuroblastoma fifteen patient median age year studi twelv relaps massiv chemotherapi autolog bone marrow transplant abmt primari refractori diseas convent chemotherapi continu infus cours doubl treatment period break cytapheresi lak progenitor cell rest period vitro cultur lak cell second cycl therapi phenotyp function analysi immunolog paramet therapeut protocol toxic signific toxic death cardiotox respiratori distress reinfus larg amount lak cell case sever toxic patient statu ie heavi pretreat signific clinic respons immunolog monitor phenotyp function modif patient initi treatment unexpect absenc evolut paramet therapi origin immun dysfunct clear failur therapi futur studi therapi neuroblastoma cours diseas